180eP ECOG performance status 2 or higher in EMA labels for advanced non-small cell lung cancer: A cross-sectional analysis of EU SmPCs

J.D. Benitez Fuentes; E. Navarro Vicente; Ana Sánchez; A. Moratiel Pellitero; J. Gomez Ulla; A. Ferrández Arias; M. Guirado; R. Lastra del Prado

doi:10.1016/j.esmoop.2026.106487

March 17, 2026ESMO OpenOpen Access

180eP ECOG performance status 2 or higher in EMA labels for advanced non-small cell lung cancer: A cross-sectional analysis of EU SmPCs

View Full Paper

Ask AI

Bookmark

Share

Key Points

The goal is to analyze the relationship between ECOG performance status and PD-L1 expression in advanced non-small cell lung cancer.
Conducted a cross-sectional analysis of EU SmPCs.
Evaluated patients with performance status 2 or higher.
Assessed the incidence of immune-related adverse events and cutaneous adverse events.
Higher PD-L1 expression is associated with significant prognostic indicators.
Pruritus is identified as a notable immune-related adverse event.
Low frequency of grade 3 adverse events suggests improvements in management of skin toxicities.

Implication

Cross-sectional analysis reveals key prognostic indicators in advanced non-small cell lung cancer, suggesting implications for personalized treatment.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fuentes et al. (2026) studied this question.

synapsesocial.com/papers/69be34886e48c4981c672bb9 https://doi.org/10.1016/j.esmoop.2026.106487

View Full Paper

Ask AI

Bookmark

Share

180eP ECOG performance status 2 or higher in EMA labels for advanced non-small cell lung cancer: A cross-sectional analysis of EU SmPCs

Key Points

Implication

Abstract

Discussion

Cite This Study

180eP ECOG performance status 2 or higher in EMA labels for advanced non-small cell lung cancer: A cross-sectional analysis of EU SmPCs

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading